Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to describe an immune activation profile of people at risk of insulin resistance based on a wide range of markers which will allow easy identification of patients at risk.

Official Title
-----------------
Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69

Conditions
-----------------
Insulin Resistance, Metabolic Syndrome X

Intervention / Treatment
-----------------
* Other: Blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient has been informed of the study, its objectives, constraints and the patient rights The patient must have given their free and informed consent and signed the consent form The patient is aged 55-69 Exclusion Criteria: The subject is participating in an interventional category 1 study The patient has participated in another category 1 interventional study in the last 3 months The patient is in a period of exclusion determined by a previous study The patient is under safeguard of justice or state guardianship The subject refuses to sign the consent The subject does not understand the information

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients aged 55-60<br> | Other: Blood test<br>* 6ml blood sample taken<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cluster of Differentiation 4 (CD4+) T cell subpopulations | immunosenescence; number/mm3 | Day 0 | 
| Cluster of Differentiation 8 (CD8+) T cell subpopulations | immunosenescence; number/mm3 | Day 0 | 
| B cell subpopulations | flow cytometry | Day 0 | 
| Natural killer (NK) cell subpopulations | immunosenescence; number/mm3 | Day 0 | 
| sCD14 level | ng/ml, enzyme-linked immunosorbent assays (ELISA) | Day 0 | 
| 16 ribosomal ribonucleic acid (rRNA) levels | polymerase chain reaction (PCR); copies/µl | Day 0 | 
| lipopolysaccharide (LPS)-binding protein level | ELISA; µg/mL | Day 0 | 
| Intestinal Fatty Acid Binding Protein level | ELISA; pg/mL | Day 0 | 
| Total cholesterol | mM/L | Day 0 | 
| High Density Lipoprotein | mM/L | Day 0 | 
| Low Density Lipoprotein | mM/L | Day 0 | 
| fasting glycemia |  | Day 0 | 
| fasting insulinemia | mIU/L | Day 0 | 
| γ-glutamyl transpeptidase level |  | Day 0 | 
| glutamic pyruvic transaminase |  | Day 0 | 
| hip circumference | cm | Day 0 | 
| waist circumference | cm | Day 0 | 
| minimal arterial tension | mmHg | Day 0 | 
| maximal arterial tension | mmHg | Day 0 | 
| Cluster of Differentiation 163 (CD163) level | ng/ml, enzyme-linked immunosorbent assays (ELISA) | Day 0 | 
| soluble tumor necrosis factor-alpha receptor I (sTNFRI) level | ng/ml, enzyme-linked immunosorbent assays (ELISA) | Day 0 | 
| soluble endothelial protein C Receptro (sEPCR) level | ng/ml, enzyme-linked immunosorbent assays (ELISA) | Day 0 | 
| tissue plasminogen activator (tPa) level | ng/ml, enzyme-linked immunosorbent assays (ELISA) | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of insulin and metabolic syndrome | % subjects | Day 0 | 
| Link between immune activation profile and other features of metabolic syndrome | logistic regression of individual markers | Day 0 | 
| Immune activation linked to the profile | logistic regression | Day 0 |